[go: up one dir, main page]

AR109209A1 - Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas - Google Patents

Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas

Info

Publication number
AR109209A1
AR109209A1 ARP170102166A ARP170102166A AR109209A1 AR 109209 A1 AR109209 A1 AR 109209A1 AR P170102166 A ARP170102166 A AR P170102166A AR P170102166 A ARP170102166 A AR P170102166A AR 109209 A1 AR109209 A1 AR 109209A1
Authority
AR
Argentina
Prior art keywords
prevention
treatment
pharmaceutical composition
neurodegenerative diseases
radotinib
Prior art date
Application number
ARP170102166A
Other languages
English (en)
Inventor
Han Seok Ko
Hyun Soo Ju
Soung Young Kang
Song Ei Song
Hea Un Lee
Gong Yeal Lee
Jae Soo Shin
Sae Bom Lee
Hyo Jung Yun
Hye Lin Park
Jong Seong Park
Choong Am Ahn
Hong Youb Kim
Dae Jin Cho
Dong Yeon Kim
Original Assignee
Il Yang Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Yang Pharm Co Ltd filed Critical Il Yang Pharm Co Ltd
Publication of AR109209A1 publication Critical patent/AR109209A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica para la prevención o el tratamiento de enfermedades neurodegenerativas, que comprende una cantidad eficaz de radotinib o una sal farmacéuticamente aceptable de éste.
ARP170102166A 2016-08-01 2017-07-31 Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas AR109209A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160097863 2016-08-01

Publications (1)

Publication Number Publication Date
AR109209A1 true AR109209A1 (es) 2018-11-07

Family

ID=61073817

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102166A AR109209A1 (es) 2016-08-01 2017-07-31 Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas

Country Status (4)

Country Link
KR (1) KR102421303B1 (es)
AR (1) AR109209A1 (es)
TW (1) TW201808294A (es)
WO (1) WO2018026150A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102618168B1 (ko) * 2018-07-06 2023-12-27 일양약품주식회사 프리온 질환의 예방 또는 치료를 위한 약제학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2844256B1 (en) 2012-05-02 2023-02-22 Georgetown University Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors
US20140127157A1 (en) * 2012-11-05 2014-05-08 Novartis Ag Antiviral activity of tyrosine kinase inhibitors against hepatitus c virus

Also Published As

Publication number Publication date
WO2018026150A1 (en) 2018-02-08
TW201808294A (zh) 2018-03-16
KR20180015085A (ko) 2018-02-12
KR102421303B1 (ko) 2022-07-18

Similar Documents

Publication Publication Date Title
MX2024004439A (es) Agentes terapeuticos para enfermedades neurodegenerativas
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2017009449A (es) Inhibidor jak.
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
CR20160538A (es) Combinación
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
DOP2017000178A (es) Inhibidores selectivos de bace1
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
SV2016005313A (es) Derivados de carboxamida
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2019008181A (es) Inhibidores selectivos hdac6, metodos de preparacion y aplicacion de los mismos.
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
MX2019010108A (es) Derivados de azetidina.
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure